BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 33916057)

  • 1. Impact of Different JAK Inhibitors and Methotrexate on Lymphocyte Proliferation and DNA Damage.
    Reddig A; Voss L; Guttek K; Roggenbuck D; Feist E; Reinhold D
    J Clin Med; 2021 Apr; 10(7):. PubMed ID: 33916057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
    McInnes IB; Byers NL; Higgs RE; Lee J; Macias WL; Na S; Ortmann RA; Rocha G; Rooney TP; Wehrman T; Zhang X; Zuckerman SH; Taylor PC
    Arthritis Res Ther; 2019 Aug; 21(1):183. PubMed ID: 31375130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
    Ho Lee Y; Gyu Song G
    J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. JAK inhibitors impair GM-CSF-mediated signaling in innate immune cells.
    Fujita Y; Matsuoka N; Temmoku J; Furuya-Yashiro M; Asano T; Sato S; Matsumoto H; Watanabe H; Kozuru H; Yatsuhashi H; Kawakami A; Migita K
    BMC Immunol; 2020 Jun; 21(1):35. PubMed ID: 32539713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Janus kinase inhibitors : State of the art in clinical use and future perspectives].
    Alten R; Mischkewitz M; Stefanski AL; Dörner T
    Z Rheumatol; 2020 Apr; 79(3):241-254. PubMed ID: 32219519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases.
    Taylor PC; Choy E; Baraliakos X; Szekanecz Z; Xavier RM; Isaacs JD; Strengholt S; Parmentier JM; Lippe R; Tanaka Y
    Rheumatology (Oxford); 2024 Feb; 63(2):298-308. PubMed ID: 37624925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.
    Atzeni F; Popa CD; Nucera V; Nurmohamed MT
    Expert Rev Clin Immunol; 2022 Mar; 18(3):233-244. PubMed ID: 35129033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. JAK inhibitors differentially modulate B cell activation, maturation and function: A comparative analysis of five JAK inhibitors in an
    Frede N; Lorenzetti R; Hüppe JM; Janowska I; Troilo A; Schleyer MT; Venhoff AC; Voll RE; Thiel J; Venhoff N; Rizzi M
    Front Immunol; 2023; 14():1087986. PubMed ID: 36776828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
    Mitchell TS; Moots RJ; Wright HL
    Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of Janus Kinases Limits Pro-Inflammatory but Also Immunosuppressive Circuits in the Crosstalk between Synovial Fibroblasts and Lymphocytes.
    Yao N; Tretter T; Kvacskay P; Merkt W; Blank N; Lorenz HM; Tykocinski LO
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function.
    Adam S; Simon N; Steffen U; Andes FT; Scholtysek C; Müller DIH; Weidner D; Andreev D; Kleyer A; Culemann S; Hahn M; Schett G; Krönke G; Frey S; Hueber AJ
    Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Janus Kinase Inhibitors in Rheumatoid Arthritis: An Update on the Efficacy and Safety of Tofacitinib, Baricitinib and Upadacitinib.
    Harrington R; Harkins P; Conway R
    J Clin Med; 2023 Oct; 12(20):. PubMed ID: 37892827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future.
    Angelini J; Talotta R; Roncato R; Fornasier G; Barbiero G; Dal Cin L; Brancati S; Scaglione F
    Biomolecules; 2020 Jul; 10(7):. PubMed ID: 32635659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of janus kinase inhibitors and methotrexate combination on malignancy in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.
    Solipuram V; Mohan A; Patel R; Ni R
    Auto Immun Highlights; 2021 Apr; 12(1):8. PubMed ID: 33910632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis.
    Biggioggero M; Becciolini A; Crotti C; Agape E; Favalli EG
    Drugs Context; 2019; 8():212595. PubMed ID: 31692920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK Inhibitors and Modulation of B Cell Immune Responses in Rheumatoid Arthritis.
    Moura RA; Fonseca JE
    Front Med (Lausanne); 2020; 7():607725. PubMed ID: 33614673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Maintenance of Baricitinib and Tofacitinib in Real Life.
    Deprez V; Le Monnier L; Sobhy-Danial JM; Grados F; Henry-Desailly I; Salomon-Goëb S; Rabin T; Ristic S; Fumery M; Fardellone P; Goëb V
    J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33081099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Janus kinase inhibitors alter NK cell phenotypes and inhibit their antitumour capacity.
    Meudec L; Richebé P; Pascaud J; Mariette X; Nocturne G
    Rheumatology (Oxford); 2023 Aug; 62(8):2855-2863. PubMed ID: 36583542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Janus kinase inhibitors in the treatment of rheumatoid arthritis: a systemic literature review.
    Jegatheeswaran J; Turk M; Pope JE
    Immunotherapy; 2019 Jun; 11(8):737-754. PubMed ID: 30955397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.